Glass Pharms
Articles by
Opinion on UK Medical Cannabis Growth
Opinion Piece on UK Medical Cannabis The growth of UK medical cannabis has been significant, albeit slower than other comparable countries such as Germany or Australia. This opinion piece, published in the Business of Cannabis, explores the UK market growth. Read More
CIC Masterclass
James Duckenfield delivering masterclass on UK medical cannabis regulations and microbial loads Our CEO, James Duckenfield, presented on UK regulations and in particular how UK standards are significantly higher than competitors in other countries. The Cannabis Industry Council event took place at law firm Irwin Mitchell.
100th Shipment Milestone
100th Weekly Shipment Glass Pharms operates a continuous cultivation facility, allowing us to ship fresh product to customers every week. Last week, we reached a milestone with our 100th weekly shipment.
Exploring risk in the medical cannabis supply chain
Supply Chain Risk Report Glass Pharms contributed to this insightful view of supply chain risk in medical cannabis as it matures to a substantial industry. This Relm Risk Briefing: Cannabis 2026 shares learnings from that experience. It investigates how regulation, insurance, and operational practice intersect across the global supply chain, drawing on data and conversations with market leaders who are setting new standards in safety, sustainability, and accountability. Read More
Coverage on S4C
Featured on S4C Glass Pharms featured on @S4C Supporting the conversation on the future of pharmaceutical cannabis in the UK. Watch now from 06:56–09:57
Featured on BBC iPlayer
Featured as part of a documentary on cannabis in the UK Glass Pharms featured on @BBCiPlayer Supporting the conversation on the future of pharmaceutical cannabis in the UK. Watch now from 06:56–09:57